title: Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
abstract: Treatment of retroperitoneal fibrosis usually involves corticosteroids with or without other immunomodulating medications or tamoxifen.  Rituximab, a monoclonal antibody that specifically targets CD20 on the surface of B-cells, is effective in achieving complete remission of proteinuria in patients with idiopathic membranous nephropathy. We describe a case of a 45 years old man with idiopathic membranous glomerulonephritis (with proteinuria of more than 30 grams/24 hours) and simultaneously with idiopathic retroperitoneal fibrosis (with large number of cells CD20 in the histologic image). The patient did not tolerate the treatment by cyclophosphamide, and as rescue therapy, administration of rituximab was indicated with excellent effect. We recorded promptreduction of proteinuria and significant reduction of retroperitoneal fibrosis. Rituximab is effective in treatment of idiopathic retroperitonea lfibrosis with positivity of CD20 cells, as well as in treatment of idiopathic membranous glomerulonephritis.
authors.affiliation: Surgery Clinic and Transplant Center, University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia. idedinska@yahoo.co.uk.
authors.forename: Ivana
authors.initials: I
authors.lastname: Dedinská
authors.forename: Daniel
authors.initials: D
authors.lastname: Svetlík
authors.forename: Katarina
authors.initials: K
authors.lastname: Adamicova
authors.forename: Katarina
authors.initials: K
authors.lastname: Machalekova
authors.forename: Pavel
authors.initials: P
authors.lastname: Makovicky
authors.forename: Alena
authors.initials: A
authors.lastname: Jezikova
authors.forename: Ludovít
authors.initials: L
authors.lastname: Laca
authors.forename: Juraj
authors.initials: J
authors.lastname: Miklusica
authors.forename: Peter
authors.initials: P
authors.lastname: Galajda
authors.forename: Marian
authors.initials: M
authors.lastname: Mokan
mesh_terms: D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology; D012185:Retroperitoneal Fibrosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D000069283:Rituximab